Yamaguchi Megu, Yamada Yuya, Hosokawa Yoshiya, Iwamoto Ryuya, Tamba Sachiko, Ihara Arisa, Yamamoto Koji, Hoshida Yoshihiko, Matsuzawa Yuji
Department of Endocrinology and Metabolism, Sumitomo Hospital, Osaka.
Intern Med. 2010;49(15):1557-63. doi: 10.2169/internalmedicine.49.3607. Epub 2010 Aug 2.
A 30-year-old woman had a history of prolactinoma and primary hyperparathyroidism. She was diagnosed as having multiple endocrine neoplasia type 1 with gastrinoma and liver metastases. Octreotide therapy was started and the serum gastrin level decreased immediately. Octreotide continued to suppress gastrin secretion over the next 7 years. The Ki67/MIB1 proliferation index of this tumor was only 0.5 % and somatostatin receptor (SSTR) 2 expression was very strong in both 2002 and 2009. This case suggests the importance of investigating the Ki67/MIB1 index and SSTR expression in patients with metastatic gastrinoma.
一名30岁女性有催乳素瘤和原发性甲状旁腺功能亢进病史。她被诊断为1型多发性内分泌肿瘤合并胃泌素瘤及肝转移。开始使用奥曲肽治疗，血清胃泌素水平立即下降。在接下来的7年里，奥曲肽持续抑制胃泌素分泌。该肿瘤的Ki67/MIB1增殖指数仅为0.5%，2002年和2009年生长抑素受体（SSTR）2表达均非常强。该病例提示在转移性胃泌素瘤患者中研究Ki67/MIB1指数和SSTR表达的重要性。
